$Zevra Therapeutics (ZVRA.US)$ NEWS Zevra Therapeutics Prese...
NEWS
Zevra Therapeutics Presents New Data on the Long-Term Safety and Efficacy of Arimoclomol as a Treatment for Niemann-Pick Disease Type C at the SIMD 45th Annual Meeting
New long-term real-world data from Zevra's Expanded Access Program for Arimoclomol in treating Niemann-Pick Disease Type C was highlighted at the SIMD 45th Annual Meeting.
The data showed a consistent safety profile and a clinically meaningful slowing of disease progression in adults with NPC.
The presentation by Kristina Julich, M.D., showcased positive clinical benefits and added to the evidence supporting Arimoclomol's effectiveness in treating NPC.
Zevra remains committed to collaborating with the FDA for the review of Arimoclomol's NDA ahead of the PDUFA date on September 21, 2024.
New long-term real-world data from Zevra's Expanded Access Program for Arimoclomol in treating Niemann-Pick Disease Type C was highlighted at the SIMD 45th Annual Meeting.
The data showed a consistent safety profile and a clinically meaningful slowing of disease progression in adults with NPC.
The presentation by Kristina Julich, M.D., showcased positive clinical benefits and added to the evidence supporting Arimoclomol's effectiveness in treating NPC.
Zevra remains committed to collaborating with the FDA for the review of Arimoclomol's NDA ahead of the PDUFA date on September 21, 2024.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
826Followers
62Following
5537Visitors
Follow